Helga Gardarsdottir, Utrecht University, Utrecht, the Netherlands & University of Iceland, Reykjavik, Iceland, Chair
Larus S Gudmundsson, University of Iceland, Reykjavik, Iceland
Freyja Jonsdottir, University of Iceland, Reykjavik, Iceland & Landspitali University Hospital, Reykjavík, Iceland
Martin Ingi Sigurdsson, University of Iceland, Reykjavik, Iceland & Landspitali University Hospital, Reykjavík, Iceland
Andrew Bate, GSK, United Kingdom
Maurizio Sessa, University of Copenhagen, Copenhagen, Denmark
Miyuki Hsing-Chun Hsieh, ISPE Student Council Co-Chair
Claire Huang, ISPE Student Council Co-Chair
Judith Maro, ISPE Education Committee Co-Chair
Debbie Layton, ISPE Educational Committee Co-Chair
James Vrac, ISPE Executive Secretary
Jennifer Lanphere, ISPE Staff
Christine Morgan, ISPE Staff
| 7:00-5:00pm | Registration |
| 8:30-12:30pm | Introduction to Pharmacoepidemiology |
| 8:30-12:30pm | 2023 Scientific Program Committee Meeting |
| 12:30-1:30pm | Lunch |
| 1:30-5:30pm | Advanced Pharmacoepidemiology |
| 5:30-7:00pm | Welcome Reception |
| 8:00-9:00am | Exhibits/Poster viewing |
| 8:00-5:00pm | Registration |
| 9:00-9:15am | Welcome and Introductions (ISPE President/ISPE MY Chair Sci committee) |
| 9:15-11:00am | Plenary Session I: Real time use of real world data for decision making |
| The COVID-19 pandemic triggered an unprecedent push towards high need for generation and use of real world data to support timely decisions. This session will provide insights into clinical and policy drive decision making at the national and international level. Moderators: Lárus S. Guðmundsson, associate professor, University of Iceland 9:15-9:45: Disseminating Covid19 science: the Iceland experience Martin Ingi Sigurdsson, Professor of Anesthesiology and Critical Care Medicine, University of Iceland 9:45-10:15: Contact Tracing in Covid-19: Data and Digitization Guðrún Aspelund, Chief Epidemiologist, Icelandic Directorare of Health 10:15-10:45: Value of real world data for decision making at the European level Menno van der Elst, EMA Pharmacovigilance Risk Assessment Commitee (PRAC) member, Dutch Medicines Evaluation Board. 10:45-11:00: Discussion |
|
| 11:00-11:30am | Coffee break/Exhibit/Poster Viewing |
| 11:30-1:15pm | Plenary Session II: Pandemic driven (real world) data shifts |
| The pandemic has impacted our lifes in various ways during the past years. The impact on healthcare can be traced through the health care data that was generated during this time. In this session we will showcase what this means for us as pharmacoepidemiologists and our future studies that rely on use of health care data. Moderators: Helga Gardarsdottir, associate professor, Utrecht University & University of Iceland 11:30-12:00:Impact of COVID-19 pandemic on health care seeking behaviour, real-world data capture, and nonrandomized real-world evidence studies Anne Mobley Butler, Assistant Professor, Washington University in St. Louis, USA 12:00-12:30: Ways COVID-19 may impact unrelated pharmacoepidemiologic research Michael Webster-Clark, post-doctoral fellow, McGill University, Canada 12:30-13:00: The changing landscape of Nordic pharmacoepidemiology during the COVID-19 pandemic and prospects for the post-pandemic period Morten Andersen, professor, Copenhagen University, Denmark 13:00-13:15: Discussion |
|
| 1:15-2:15pm | Lunch break/Exhibit/Poster Viewing |
| 2:15-3:45pm | Student Oral Session I |
| 3:45-4:15pm | Coffee break/Exhibit/Poster Viewing |
| 4:15-5:45pm | Student Oral Session II |
| 5:45-6:00pm | Closing Remarks |
| 6:30-7:30pm | Student/Early Career Professionals Meet & Greet |
| 8:00-9:00am | Exhibits/Poster viewing |
| 8:00-5:00pm | Registration |
| 9:00-10:45am |
Plenary Session III: Real-world data for precision medicine: a pharmacoepidemiological perspective |
|
The COVID-19 pandemic has pushed forward research on tailor treatment and interventions to unique individual or population-level traits complementing conventional pharmacoepidemiological approaches. In this session, we will showcase precision medicine and precision public health approaches used for pharmacoepidemiological safety and effectiveness surveillance. |
|
| 10:45-11:15am | Coffee break/Exhibit/Poster Viewing |
| 11:15-1:00pm | Plenary Session IV: Future innovation and outlook for the field of pharmacoepidemiology |
| The pandemic has and is acting as a stimulus for innovation right across the field of pharmacoepidemiology. In what areas are we seeing most impetus? A range of different stakeholders will share their perspective on the changes that are and need to occur as Pharmacoepdiemiology advances. Moderators: Andrew Bate, Vice president, Head of Safety Innovation & Analytics, GSK Susana Perez-Gutthan, Vice President, Global Head Epidemiology, RTI International 11:00-11:30: The regulatory perspective Alison Cave, PhD, Chief Safety Officer, MHRA 11:30-12:00:The academic perspective Robbert Platt, PhD, Professor, McGill University (CNODES) 12:00-12:30:The industry perspective Jamie Geier, Global Head, Quantitative Safety & Epidemiology, Novartis 12:30-12:45: Discussion |
|
| 1:00-2:00pm | Lunch break/Exhibit/Poster Viewing |
| 2:00-3:30pm | Student Oral Session III |
| 3:30-4:00pm | Coffee break/Exhibit/Poster Viewing |
| 4:00-5:30pm | Student Oral Session IV |
| 5:30-5:45pm | Closing Remarks & Adjournment |
Schedule as of 12.13.22
*all times in GMT